[FLML] Flamel Technologies S.A.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 512.2 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 10.21 Change: 0.27 (2.72%)
Ext. hours: Change: 0 (0%)

chart FLML

Refresh chart

Description: Flamel Technologies SA, a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary polymer based technology. The company owns and develops drug delivery platforms, such as Micropump that allows generating and marketing modified and/or controlled release of solid and oral dosage formulations of drugs; and LiquiTime, which develops modified/controlled release of liquid formulations for patients having issues swallowing tablets or capsules. Its drug delivery platforms also comprise Trigger Lock that develops tamper-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, which develops extended/modified release of injectable dosage formulations of drugs. The company?s lead products include Bloxiverz, a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Coreg CR, a non-selective antagonist of

Fundamental Ratios
Shares Outstanding41.24 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow-41.49 ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-80 K Cash From Investing Activities-23.43 M Cash From Operating Activities25.27 M Gross Profit29.1 M
Net Profit11.65 M Operating Profit10.21 M Total Assets186.41 M Total Current Assets129.33 M
Total Current Liabilities77.65 M Total Debt123.19 M Total Liabilities164.16 M Total Revenue32.73 M
Technical Data
High 52 week14.89 Low 52 week7.85 Last close10.39 Last change0%
RSI59.38 Average true range3.84 Beta0.69 Volume53.92 K
Simple moving average 20 days1.34% Simple moving average 50 days0.13% Simple moving average 200 days-9.8%
Performance Data
Performance Week0% Performance Month0% Performance Quart-17.87% Performance Half-16.68%
Performance Year3.49% Performance Year-to-date0% Volatility daily1.5% Volatility weekly3.36%
Volatility monthly6.89% Volatility yearly23.88% Relative Volume272.8% Average Volume93.67 K
New High New Low

News

2017-03-31 17:08:19 | AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Financial Statement

2017-03-30 16:03:00 | Avadel Pharmaceuticals Announces Planned Reduction of French Workforce

2017-03-28 17:24:44 | AVADEL PHARMACEUTICALS PLC Files SEC form 10-K, Annual Report

2017-03-17 06:03:37 | AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits

2017-03-07 16:08:40 | AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Amendment or Waiver to Code of Ethics, Financial Statements and Exhibi

2017-03-07 07:06:28 | Avadel tops Street 4Q forecasts

2017-03-07 07:00:00 | Avadel Pharmaceuticals Announces $25 Million Share Repurchase Program

2017-03-07 06:34:00 | 6:34 am Avadel Pharmaceuticals beats by $0.02, beats on revs; reaffirms FY17 EPS, revs guidance

2017-03-07 06:30:00 | Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Results

2017-03-02 10:01:51 | AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Other Events

2017-03-02 07:30:00 | Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

2017-02-24 08:30:01 | Avadel Pharmaceuticals AVDL Looks Good: Stock Up 5.3%

2017-02-16 06:37:53 | AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Other Events

2017-02-14 07:30:00 | Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Results

2017-02-06 15:55:36 | AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Other Events

2017-02-06 07:30:00 | Avadel Pharmaceuticals to Present at Two Upcoming Investor Conferences

2017-01-11 16:05:01 | AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2017-01-06 13:52:18 | AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Other Events

2017-01-06 13:04:06 | AVADEL PHARMACEUTICALS PLC Financials

2017-01-05 11:57:22 | AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2017-01-05 08:18:24 | CORRECTING and REPLACING – Avadel Pharmaceuticals Provides 2017 Guidance and Business Update

2017-01-05 07:30:00 | Avadel Pharmaceuticals Provides 2017 Guidance and Business Update

2017-01-03 16:03:00 | Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Commercial Officer

2017-01-03 07:30:00 | Flamel Technologies Completes Cross-Border Merger and Becomes Avadel Pharmaceuticals plc

2016-12-19 15:38:22 | FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Other Events

2016-12-16 08:00:00 | Flamel Technologies Doses First Patient in REST-ON Phase III Trial of FT218 for Excessive Daytime Sleepiness & Cataplexy

2016-12-15 09:23:03 | Here is What Hedge Funds Think About Tejon Ranch Company TRC

2016-12-05 12:07:44 | ETFs with exposure to Flamel Technologies SA : December 5, 2016

2016-12-05 07:59:57 | Is Flamel Technologies S.A. ADR FLML A Good Stock To Buy?

2016-11-23 13:04:10 | FLAMEL TECHNOLOGIES SA Financials

2016-11-22 10:43:21 | Flamel Technologies SA :FLML-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016

2016-11-17 17:08:10 | FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2016-11-15 16:03:05 | FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2016-11-14 17:46:56 | FLAMEL TECHNOLOGIES SA Files SEC form 10-Q, Quarterly Report

2016-11-14 11:12:22 | Horizon Pharma PLC HZNP, Flamel Technologies S.A. ADR FLML & More: Why Should You Consider Following Broadfin Capital’s Investment Moves?

2016-11-10 15:02:25 | FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Other Events

2016-11-09 16:01:00 | Flamel Technologies to Present Jefferies 2016 London Healthcare Conference

2016-11-07 17:32:16 | FLAMEL TECHNOLOGIES SA Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial Statements and

2016-11-07 16:50:18 | Edited Transcript of FLML earnings conference call or presentation 7-Nov-16 3:00pm GMT

2016-11-07 09:13:00 | CORRECTION - Flamel Technologies Reports Third Quarter 2016 Results

2016-11-07 08:05:35 | FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, F

2016-11-07 07:44:50 | Flamel reports 3Q loss

2016-11-07 07:30:00 | Flamel Technologies Reports Third Quarter 2016 Results

2016-11-07 07:07:06 | Q3 2016 Flamel Technologies SA Earnings Release - Before Market Open

2016-10-27 09:52:13 | FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Other Events

2016-10-25 16:03:00 | Flamel Technologies to Report Third Quarter 2016 Results

2016-10-20 16:49:18 | FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits

2016-10-06 17:13:16 | FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2016-10-06 07:30:00 | Flamel Technologies Reaches Agreement With FDA on Protocol for Phase III Pivotal Trial of FT218

2016-09-29 09:38:26 | ETF’s with exposure to Flamel Technologies SA : September 29, 2016